Ruxolitinib add-on in corticosteroid-ref ractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients-Reference-Cited by-同舟云学术

Ruxolitinib add-on in corticosteroid-ref ractory graft-vs-host disease after allogeneic stem cell transplantation: Results from a retrospective study on 38 Chinese patients

Published:2020-03-26 Issue:6 Volume:8 Page:1065-1073
ISSN:2307-8960
Container-title:World Journal of Clinical Cases
language:
Short-container-title:WJCC

Author:

Dang Si-Hua,Liu Qin,Xie Rong,Shen Na,Zhou Shu,Shi Wei,Liu Wen,Zou Ping,You Yong,Zhong Zhao-Dong

Publisher

Baishideng Publishing Group Inc.

Subject

General Medicine

Reference26 articles.

1. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications

2. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease

3. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

4. Steroid-Refractory Acute GVHD: Predictors and Outcomes

5. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults;European Respiratory Journal;2024-03

2. Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study;Annals of Hematology;2023-07-20

3. Efficacy and safety of ruxolitinib for steroid-refractory graft-versus-host disease: Systematic review and meta-analysis of randomised and non-randomised studies;PLOS ONE;2022-07-29

4. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy;The Oncologist;2022-04-01

5. Ruxolitinib for Treatment of Steroid-Refractory Graft-versus-Host Disease: Real-World Data from Chinese Patients;Drug Design, Development and Therapy;2021-11